PARP inhibitors
Jump to navigation
Jump to search
PARP inhibitors are a class of cancer drugs.
PARP is an abbreviation for poly-ADP ribose polymerase.
Use
- Prostate cancer.
- Breast cancer.
- Ovarian cancer.
Drugs
- Olaparib (Lynparza).[1]
- Rucaparib (Rubraca).
- Niraparib (Zejula).
See also
References
- ↑ Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A (December 2016). "PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting". Prz Menopauzalny 15 (4): 215–219. doi:10.5114/pm.2016.65667. PMC 5327624. PMID 28250726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327624/.